Conversely, EMA has approved adjuvant atezolizumab in patients with stage IB-IIIA NSCLC, without sensitizing EGFR mutations, following cisplatin-based chemotherapy, with PD-L1 expression ≥ 50%, based on the results of the secondary endpoints of the IMpower010 trial that included DFS in patients with stage II-IIIA tumors expressing PD-L1 on 50% or more tumor cells. Here, CD274 is linked to non-small cell lung carcinoma.